ArticleSubstance use & misuse2026
Cannabis Legalization and Cannabis Use Disorder by Sex in Veterans Health Administration Patients, 2005-2019.
Article in Substance use & misuse, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundUnderstanding sex differences in the effects of cannabis legalization and increasing risk for cannabis use disorder (CUD) is important. We hypothesized that from 2005 to 2019, increases in CUD prevalence due to state medical or recreational cannabis laws (MCL; RCL) would differ among male and female veterans treated at the U.S. Veterans Health Administration (VHA), with greater increases among females.
methodsData obtained through the VHA Corporate Data Warehouse included veterans 18-75 years with ≥1 VHA primary care, emergency department, or mental health visit in a given year, 2005-2019. Staggered-adoption difference-in-difference analyses were used to estimate the role of MCL and RCL on trends in CUD diagnostic prevalence, fitting a linear binomial regression model with fixed effects for state and categorical year, time-varying cannabis law status, state-level sociodemographic covariates, patient-level age group (18-35, 36-64, 65-75 years), race and ethnicity.
resultsCUD prevalences increased in both sexes. CUD increased more in states enacting MCL and RCL than in states that did not enact CL. However, no CUD prevalence increases attributable to the change from no-CL to MCL-only or MCL to RCL differed significantly by sex, with one exception (greater in males aged 35-64).
conclusionsIncreases in CUD prevalence following MCL or RCL enactment were greater than in states with no-CL, but generally did not show differences by sex. The increases in CUD prevalence occurring for males and females throughout the study years indicate the need for cannabis use screening by medical providers and the importance of offering evidence-based treatments for CUD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.